Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL

Author:

Testi Anna Maria1ORCID,Pession Andrea2ORCID,Diverio Daniela1ORCID,Grimwade David3,Gibson Brenda4,de Azevedo Amilcar Cardoso5,Moran Lorena6,Leverger Guy7,Elitzur Sarah8,Hasle Henrik9,ten Bosch Jutte van der Werff10,Smith Owen11,De Rosa Marisa12,Piciocchi Alfonso13,Lo Coco Francesco14,Foà Robin1,Locatelli Franco1516,Kaspers Gertjan J. L.171819

Affiliation:

1. Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy;

2. Department of Pediatrics, Sant’Orsola Hospital, University of Bologna, Bologna, Italy;

3. Division of Genetics and Molecular Medicine, King’s College, London, United Kingdom;

4. Department of Paediatric Haematology, Royal Hospital for Children, Glasgow, United Kingdom;

5. Hematology/Oncology Department, Boldrini’s Children Center, Campinas, Sao Paulo, Brazil;

6. Grupo Argentino de Tratamiento de la Leucemia Aguda, Buenos Aires, Argentina;

7. Assistance Publique–Hôpitaux de Paris, Hospital Armand Trousseau, Sorbonne Universitè, Paris, France;

8. Pediatric Hematology-Oncology, Schneider Children’s Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;

9. Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark;

10. Department of Pediatrics, Universitair Ziekenhuis Brussel, Brussels, Belgium;

11. Department of Paediatric Hematology/Oncology, Our Lady’s Children’s Hospital, Dublin, Ireland;

12. Cineca Interuniversity Consortium, Bologna, Italy;

13. Gruppo Italiano Malattie Ematologiche dell’Adulto Foundation, Rome, Italy;

14. Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy;

15. Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy;

16. Department of Pediatric Sciences, University of Pavia, Pavia, Italy;

17. Pediatric Oncology, VU University Medical Center, Amsterdam, The Netherlands;

18. Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands; and

19. Dutch Childhood Oncology Group, The Hague, The Netherlands

Abstract

Key Points Risk-adapted therapy allowed achieving remarkable cure rates in an international trial on childhood APL. Reduction of the anthracycline cumulative dose coupled with ATRA extended use does not compromise the outcome of children with APL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 51 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3